BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9869522)

  • 1. Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides.
    Peoples GE; Anderson BW; Fisk B; Kudelka AP; Wharton JT; Ioannides CG
    Ann Surg Oncol; 1998 Dec; 5(8):743-50. PubMed ID: 9869522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers.
    Peoples GE; Anderson BW; Lee TV; Murray JL; Kudelka AP; Wharton JT; Ioannides CG
    Clin Cancer Res; 1999 Dec; 5(12):4214-23. PubMed ID: 10632363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The comparison of cytotoxic T-lymphocyte effects of dendritic cells stimulated by the folate binding protein peptide cultured with IL-15 and IL-2 in solid tumor.
    Kim DK; Kim JH; Kim YT; Kim JW; Ioannides CG
    Yonsei Med J; 2002 Dec; 43(6):691-700. PubMed ID: 12497651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients.
    Kim DK; Lee TV; Castilleja A; Anderson BW; Peoples GE; Kudelka AP; Murray JL; Sittisomwong T; Wharton JT; Kim JW; Ioannides CG
    Anticancer Res; 1999; 19(4B):2907-16. PubMed ID: 10652572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.
    Linehan DC; Goedegebuure PS; Peoples GE; Rogers SO; Eberlein TJ
    J Immunol; 1995 Nov; 155(9):4486-91. PubMed ID: 7594611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells.
    Ramakrishna V; Ross MM; Petersson M; Gatlin CC; Lyons CE; Miller CL; Myers HE; McDaniel M; Karns LR; Kiessling R; Parmiani G; Flyer DC
    Int Immunol; 2003 Jun; 15(6):751-63. PubMed ID: 12750359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.
    Peiper M; Goedegebuure PS; Linehan DC; Ganguly E; Douville CC; Eberlein TJ
    Eur J Immunol; 1997 May; 27(5):1115-23. PubMed ID: 9174600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shared T cell epitopes in epithelial tumors.
    Peoples GE; Smith RC; Linehan DC; Yoshino I; Goedegebuure PS; Eberlein TJ
    Cell Immunol; 1995 Sep; 164(2):279-86. PubMed ID: 7656335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
    Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
    Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer.
    Peoples GE; Goedegebuure PS; Andrews JV; Schoof DD; Eberlein TJ
    J Immunol; 1993 Nov; 151(10):5481-91. PubMed ID: 8228240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes.
    Kono K; Rongcun Y; Charo J; Ichihara F; Celis E; Sette A; Appella E; Sekikawa T; Matsumoto Y; Kiessling R
    Int J Cancer; 1998 Oct; 78(2):202-8. PubMed ID: 9754653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
    Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
    Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of naturally processed human ovarian peptides recognized by tumor-associated CD8+ cytotoxic T lymphocytes.
    Fisk B; Anderson BW; Gravitt KR; O'Brian CA; Kudelka AP; Murray JL; Wharton JT; Ioannides CG
    Cancer Res; 1997 Jan; 57(1):87-93. PubMed ID: 8988046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TCR V beta 3+ and V beta 6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers.
    Peoples GE; Yoshino I; Douville CC; Andrews JV; Goedegebuure PS; Eberlein TJ
    J Immunol; 1994 May; 152(10):4993-9. PubMed ID: 7909829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
    Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
    J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.
    Fisk B; Blevins TL; Wharton JT; Ioannides CG
    J Exp Med; 1995 Jun; 181(6):2109-17. PubMed ID: 7539040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides.
    Ioannides CG; Fisk B; Jerome KR; Irimura T; Wharton JT; Finn OJ
    J Immunol; 1993 Oct; 151(7):3693-703. PubMed ID: 7690810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer.
    Yoshino I; Peoples GE; Goedegebuure PS; Maziarz R; Eberlein TJ
    J Immunol; 1994 Mar; 152(5):2393-400. PubMed ID: 8133050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic cancer associated ascites-derived CTL recognize a nine-amino-acid peptide GP2 derived from HER2/neu.
    Peiper M; Goedegebuure PS; Izbicki JR; Eberlein TJ
    Anticancer Res; 1999; 19(4A):2471-5. PubMed ID: 10470176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in an HER-2 peptide upregulating HLA-A2 expression affect both conformational epitopes and CTL recognition: implications for optimization of antigen presentation and tumor-specific CTL induction.
    Fisk B; Savary C; Hudson JM; O'Brian CA; Murray JL; Wharton JT; Ioannides CG
    J Immunother Emphasis Tumor Immunol; 1995 Nov; 18(4):197-209. PubMed ID: 8680648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.